

The original disclosure in Japanese was released on Aug. 8, 2023 at 15:30 (GMT+9)

## Consolidated Financial Statements for the Year Ended June 30, 2023 FY2024 (April 1, 2023 - March 31, 2024) [UNAUDITED]

Company name: Takara Holdings Inc.  
Stock exchange listings: Tokyo Stock Exchange (PRIME section)  
Code number: 2531  
URL: <https://www.takara.co.jp/>  
Company representative: Mutsumi Kimura, President  
Contact: Masakazu Usami, General Manager of Public Relations& Investor Relations Dept..  
TEL: (075)241-5124

Quarterly statement filing date(as planned): August 10, 2023

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.  
2. Amounts are rounded down to the nearest million yen.

### 1. Results for the three months ended June 30, 2023 (April 1, 2023 - June 30, 2023)

#### (1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Three months ended June 30, 2023		Three months ended June 30, 2022	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	81,510	4.8	77,782	13.0
Operating income (loss)	7,101	(20.2)	8,894	(27.9)
Ordinary income (loss)	7,700	(16.8)	9,253	(27.4)
Net income (loss) attributable to owners of the parent	4,965	(5.3)	5,241	(2.0)
Net income (loss) per share (Yen)	25.11		26.51	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	11,166	(14.7)	13,091	(1.1)

#### (2) Consolidated financial position

	As of June 30, 2023	As of March 31, 2023
	(Millions of yen)	(Millions of yen)
Total assets	403,769	399,174
Net assets	256,964	255,318
Equity ratio (%)	51.2	51.1
(Reference) Equity	206,870	203,951

### 2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2023	Year ending March 31, 2024	Year ending March 31, 2024 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	38.00	-	27.00
Annual	38.00	-	27.00

Note: Correction of dividend forecast from the most recent dividend forecast: No

### 3. Forecast for the year ending March 31, 2024 (April 1, 2023 - March 31, 2024)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2023		Year ending March 31, 2024	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	170,000	3.5	355,000	1.2
Operating income (loss)	11,100	(43.4)	26,300	(30.7)
Ordinary income (loss)	11,400	(42.9)	26,800	(30.8)
Net income (loss) attributable to owners of the parent	6,700	(38.4)	15,000	(29.3)
Net income per share (Yen)	33.89		75.87	

Note: Correction of financial forecast from the most recent financial forecast: No

#### 4. Others

- (1) Material changes in subsidiaries during this period  
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No
- (2) Accounting procedures specific to quarterly consolidated financial statements : No
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
  - 1) Changes based on revisions of accounting standard: No
  - 2) Changes other than ones based on revisions of accounting standard: No
  - 3) Changes in accounting estimates: No
  - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
  - 1) Number of outstanding shares at the end of each period (Treasury stocks are included):
    - As of June 30, 2023 : 199,699,743 shares
    - As of March 31, 2023 : 199,699,743 shares
  - 2) Number of treasury stocks at the end of each period:
    - As of June 30, 2023 : 1,995,612 shares
    - As of March 31, 2023 : 1,995,612 shares
  - 3) Average number of outstanding shares in each period
    - Three months ended June 30, 2023 : 197,704,131 shares
    - Three months ended June 30, 2022 : 197,704,166 shares

## Contents of the attached document

1. Qualitative Information for the Three Months Ended June 30, 2023 .....	2
(1) Consolidated Financial Results .....	2
(2) Consolidated Financial Position .....	3
(3) Qualitative Information Regarding Consolidated Forecasts .....	4
2. Consolidated Quarterly Financial Statements and Primary Notes .....	5
(1) Consolidated Balance Sheets .....	5
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income .....	7
(Consolidated Statements of Income) .....	7
(For the Three Months Ended June 30, 2023 and 2022)	
(Consolidated Statements of Comprehensive Income) .....	8
(For the Three Months Ended June 30, 2023 and 2022)	
(3) Notes to Consolidated Financial Statements .....	9
(Notes on Premise of Going Concern) .....	9
(Notes on Material Changes in Shareholders' Equity) .....	9
(Segment Information) .....	9

### ○ Supplement for the Consolidated Quarterly Financial Statements

## 1. Qualitative Information for the Three Months Ended June 30, 2023

### (1) Consolidated Financial Results

In the three months ended June 30, 2023, net sales increased 4.8% year on year to ¥81,510 million, gross profit increased 2.0% year on year to ¥28,039 million, and SG&A expenses increased 12.6% year on year to ¥20,937 million. Operating income decreased 20.2% year on year to ¥7,101 million, ordinary income decreased 16.8% year on year to ¥7,700 million, and net income attributable to owners of the parent decreased 5.3% year on year to ¥4,965 million.

Results by business segment were as follows.

#### [Takara Shuzo]

In the three months ended June 30, 2023, although sales of shochu and sake decreased year on year, sales of light-alcohol refreshers, *Hon Mirin* and raw alcohol increased.

As a result, net sales for Takara Shuzo increased 2.7% year on year to ¥31,773 million. Cost of sales decreased 1.6% year on year to ¥23,389 million, mainly due to decreased sales volumes and a change in the sales mix, despite the impact of soaring raw material and fuel prices. Gross profit increased 16.9% year on year to ¥8,383 million. SG&A expenses decreased 4.6% year on year to ¥5,788 million due to a decrease in transportation costs and advertising expenses. Operating income was up 134.2% year on year to ¥2,595 million.

#### [Takara Shuzo International Group]

In the three months ended June 30, 2023, net sales of the Overseas Alcoholic Beverages Business increased year on year mainly due to continued growth in sales of whiskey in the U.S. and U.K. as well as an increase in sales of sake. Net sales of the Japanese Food Wholesale Business in overseas markets also increased as the eating and drinking establishment market continued to perform well, with the development of new business bases also contributing positively.

As a result, net sales for the Takara Shuzo International Group increased 27.4% year on year to ¥37,432 million. Cost of sales increased 24.7% year on year to ¥25,228 million in line with the increase in net sales. Consequently, gross profit increased 33.6% year on year to ¥12,203 million. SG&A expenses were up 31.3% year on year to ¥8,616 million, primarily due to an increase in personnel expenses and transportation costs, and operating income was up 39.4% year on year to ¥3,587 million.

#### [Takara Bio Group]

In the three months ended June 30, 2023, although sales of CDMO and gene therapy increased year on year, sales of reagents and instruments decreased. As a result, net sales for the Takara Bio Group decreased 34.9% year on year to ¥9,176 million. In particular, sales of testing-related reagents decreased, mainly due to the convergence of the COVID-19 pandemic and changes in the legal categorization of the virus. Cost of sales decreased 32.5% year on year to ¥2,683 million, mainly due to a decrease in net sales. Consequently, gross profit decreased 35.9% year on year to ¥6,493 million. SG&A expenses were up 8.6% year on year to ¥6,069 million, primarily due to increases in personnel expenses and R&D expenses. Operating income decreased 90.7% year on year to ¥423 million.

#### [Other]

In the three months ended June 30, 2023, net sales of the Other segment decreased 5.5% year on year to ¥7,623 million due to decreased sales in the transportation business and the printing business. Cost of sales decreased 5.7% year on year to ¥6,466 million. Consequently, gross profit decreased 4.2% year on year to ¥1,156 million. SG&A expenses decreased 1.1% year on year to ¥469 million due to decreases in personnel expenses and sales promotion expenses, and operating income was down 6.2% year on year to ¥686 million.

## Breakdown of sales results by product category

Segment		Equivalent Period of Previous Fiscal Year (From April 1, 2022, to June 30, 2022)	Period under Review (From April 1, 2023, to June 30, 2023)	YoY Comparison
	Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo				
	Shochu	10,821	9,612	(11.2)
	Sake	2,395	2,292	(4.3)
	Light-alcohol refreshers	9,707	10,684	10.1
	Other alcoholic beverages	1,399	1,486	6.3
	<i>Hon Mirin</i>	2,251	2,328	3.4
	Other seasonings	2,127	2,215	4.2
	Raw alcohol, etc.	2,239	3,153	40.8
	Total	30,941	31,773	2.7
Takara Shuzo International Group				
	Overseas Alcoholic Beverages Business	3,848	4,889	27.0
	Japanese Food Wholesales Business in overseas markets	25,980	33,140	27.6
	Other	2,797	198	(92.9)
	Elimination of intra-Group transaction on consolidation	(3,256)	(796)	—
	Total	29,371	37,432	27.4
Takara Bio Group				
	Reagents	12,043	6,909	(42.6)
	Instruments	267	220	(17.5)
	CDMO	1,291	1,366	5.8
	Gene therapy	499	679	36.1
	Total	14,102	9,176	(34.9)
	Reported segment total	74,415	78,382	5.3
	Other	8,064	7,623	(5.5)
	Segment total	82,479	86,005	4.3
	Sales not allocated to business segments and intersegment transactions	(4,696)	(4,495)	—
	<b>Total</b>	<b>77,782</b>	<b>81,510</b>	<b>4.8</b>

Note: 1. Amounts include alcohol tax.

## (2) Consolidated Financial Position

As of June 30, 2023, current assets were ¥237,491 million, a decrease of ¥4,022 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in cash and deposits of ¥8,907 million, despite an increase in other in current assets of ¥3,396 million. Noncurrent assets were ¥166,278 million, an increase of ¥8,616 million compared with that at the end of the previous fiscal year. This was primarily due to increases in property, plant and equipment of ¥768 million, intangible assets of ¥569, and investments and other assets of ¥7,278 million due to an increase in the market valuation of investment securities.

As a result, total assets were ¥403,769 million, an increase of ¥4,594 million compared with that at the end of the previous fiscal year.

As of June 30, 2023, current liabilities were ¥67,300 million, a decrease of ¥154 million compared with that at the end of the previous fiscal year. Noncurrent liabilities were ¥79,503 million, an increase of ¥3,101 million compared with that at the end of the previous fiscal year.

As a result, total liabilities were ¥146,804 million, an increase of ¥2,947 million compared with that at the end of the

previous fiscal year.

As of June 30, 2023, total net assets were ¥256,964 million, an increase of ¥1,646 million compared with that at the end of the previous fiscal year. This was primarily due to increases in valuation difference on available-for-sale securities of ¥3,752 million and foreign currency translation adjustment of ¥1,576 million, offset by decreases in retained earnings of ¥2,547 million and noncontrolling interests of ¥1,272 million.

As a result, the equity ratio totaled 51.2%, compared with 51.1% at the end of the previous fiscal year.

### **(3) Qualitative Information Regarding Consolidated Forecasts**

There are no changes to the consolidated results forecasts for the six months ending September 30, 2023 and the fiscal year ending March 31, 2024 published in the financial statements on May 11, 2023.

Note: Today (August 8, 2023), the Company subsidiary Takara Bio Inc. (listed on the Prime Market of the Tokyo Stock Exchange with securities code number 4974) revised its consolidated results forecasts for the six months ending September 30, 2023, published in the financial statements on May 11, 2023; however, there are no changes to its full-year consolidated results forecast for the fiscal year ending March 31, 2024.

## 2. Consolidated Quarterly Financial Statements and Primary Notes

### (1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2023	As of June 30, 2023
<b>Assets</b>		
Current assets		
Cash and deposits	96,820	87,913
Notes and accounts receivable-trade	69,717	70,372
Merchandise and finished goods	57,812	58,630
Work in process	1,718	1,671
Raw materials and supplies	7,372	7,415
Other	8,765	12,161
Allowance for doubtful accounts	(694)	(673)
Total current assets	241,513	237,491
Noncurrent assets		
Property, plant and equipment	88,890	89,658
Intangible assets		
Goodwill	10,668	11,499
Other	5,262	5,002
Total intangible assets	15,931	16,501
Investments and other assets		
Investment securities	30,573	35,996
Other	22,328	24,184
Allowance for doubtful accounts	(64)	(62)
Total investments and other assets	52,838	60,117
Total noncurrent assets	157,661	166,278
Total assets	399,174	403,769

(Millions of Yen)

	As of Mar. 31, 2023	As of June 30, 2023
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	21,775	21,203
Short-term loans payable	4,919	4,915
Accrued alcohol tax	5,815	6,520
Accrued expenses	6,368	5,894
Income taxes payable	2,220	2,414
Provision for bonuses	3,380	4,263
Other provision	242	177
Other	22,733	21,911
Total current liabilities	67,454	67,300
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	15,186	15,178
Net defined benefit liability	8,925	8,902
Other	32,288	35,422
Total noncurrent liabilities	76,401	79,503
Total liabilities	143,856	146,804
<b>Net assets</b>		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,994	1,994
Retained earnings	163,825	161,277
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	177,363	174,815
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	12,974	16,726
Deferred gains or losses on hedges	286	380
Foreign currency translation adjustment	13,686	15,262
Remeasurements of defined benefit plans	(359)	(314)
Total accumulated other comprehensive income	26,588	32,055
Noncontrolling interests	51,366	50,094
Total net assets	255,318	256,964
Total liabilities and net assets	399,174	403,769



**(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income**

**(Consolidated Statements of Income)**

**(For the Three Months Ended June 30, 2023 and 2022)**

(Millions of Yen)

	FY2023 (Apr. 1, 2022 – June 30, 2022)	FY2024 (Apr. 1, 2023 – June 30, 2023)
Net sales	77,782	81,510
Cost of sales	50,294	53,471
Gross profit	27,488	28,039
Selling, general and administrative expenses	18,593	20,937
Operating income	8,894	7,101
Nonoperating income		
Dividends income	425	471
Other	258	275
Total nonoperating income	683	746
Nonoperating expenses		
Interest expenses	75	91
Foreign exchange losses	145	—
Other	103	56
Total nonoperating expenses	324	148
Ordinary income	9,253	7,700
Extraordinary income		
Gain on sale of noncurrent assets	251	11
Gain on sale of investment securities	—	8
Insurance claim income	652	—
Total extraordinary income	903	19
Extraordinary loss		
Loss on sale and retirement of noncurrent assets	10	27
Other	12	—
Total extraordinary losses	22	27
Income before income taxes	10,134	7,692
Income taxes-current	2,499	2,754
Income taxes-deferred	551	(514)
Total income taxes	3,051	2,240
Net income	7,083	5,451
Net income attributable to the noncontrolling interest	1,841	486
Net income attributable to owners of the parent	5,241	4,965

**(Consolidated Statements of Comprehensive Income)**  
**(For the Three Months Ended June 30, 2023 and 2022)**

(Millions of Yen)

	FY2023 (Apr. 1, 2022 – June 30, 2022)	FY2024 (Apr. 1, 2023 – June 30, 2023)
Net income	7,083	5,451
Other comprehensive income		
Valuation difference on available-for-sale securities	(648)	3,752
Deferred gains or losses on hedges	323	93
Foreign currency translation adjustment	6,291	1,817
Remeasurements of defined benefit plans	41	50
Total other comprehensive income	6,008	5,715
Comprehensive income	13,091	11,166
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	9,912	10,431
Comprehensive income attributable to noncontrolling interest	3,178	734

**(3) Notes to Consolidated Financial Statements****(Notes on Premise of Going Concern)**

No items to report.

**(Notes on Material Changes in Shareholders' Equity)**

No items to report.

**(Segment Information)****I. Equivalent Period of Previous Fiscal Year (From April 1, 2022 to June 30, 2022)****1. Net sales and Income (Loss) by Reported Segment**

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	30,734	29,336	14,101	74,172	3,610	77,782	-	77,782
Intersegment	207	34	0	242	4,454	4,696	(4,696)	-
Total	30,941	29,371	14,102	74,415	8,064	82,479	(4,696)	77,782
Segment income (loss)	1,108	2,573	4,537	8,219	732	8,952	(57)	8,894

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(57) million comprises intersegment eliminations of ¥25 million and loss of the Company not allocated to business segments of ¥(83) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

**2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment**

No items to report.

**II. Period under Review (From April 1, 2023, to June 30, 2023)****1. Net sales and Income (Loss) by Reported Segment**

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	31,524	37,348	9,176	78,049	3,461	81,510	-	81,150
Intersegment	249	83	0	333	4,162	4,495	(4,495)	-
Total	31,773	37,432	9,176	78,382	7,623	86,005	(4,495)	81,510
Segment income (loss)	2,595	3,587	423	6,606	686	7,293	(191)	7,101

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(191) million comprises intersegment eliminations of ¥(4) million and loss of the Company not allocated to business segments of ¥(187) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment  
No items to report.



2024年3月期  
第1四半期決算短信補足資料  
Supplement for the Consolidated Financial Statements  
for the First Quarter Ended June 30, 2023

1. 宝ホールディングス(連結)  
Takara Holdings Inc. -Consolidated-  
グループ別要約損益計算書  
Consolidated Statements of Income by Business Group (Summary)
2. 宝酒造  
Takara Shuzo  
要約損益計算書  
Statements of Income (Summary)
3. 宝酒造インターナショナルグループ  
Takara Shuzo International Group  
要約損益計算書  
Statements of Income (Summary)
4. タカラバイオグループ  
Takara Bio Group  
要約損益計算書  
Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)  
Six-Year Financial Summary by Business Group
6. 2024年3月期 第1四半期 参考資料  
Reference Data for the First Quarter Ended June 30, 2023

宝ホールディングス株式会社  
TAKARA HOLDINGS INC.

広報・IR部 [Public Relations & Investor Relations Dept.](#)

TEL 075(241)5124  
FAX 075(241)5126  
E-Mail [ir@takara.co.jp](mailto:ir@takara.co.jp)

### 将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

#### Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社 広報・IR部

Takara Holdings Inc. Public Relations&Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5126

E-Mail [ir@takara.co.jp](mailto:ir@takara.co.jp)

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)  
(百万円 :Millions of Yen)

	2023年3月期 第1四半期	2024年3月期 第1四半期 Apr. 1, 2023 - Jun. 30, 2023		
	実績 FY2023(1stQ) Actual(a)	実績 FY2024(1stQ) Actual(b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)
宝酒造 Takara Shuzo	30,941	31,773	831	2.7%
宝酒造インターナショナルグループ Takara Shuzo International Group	29,371	37,432	8,061	27.4%
タカラバイオ グループ Takara Bio Group	14,102	9,176	△ 4,925	△34.9%
その他 Other	8,064	7,623	△ 440	△5.5%
調整額 Adjustment	△ 4,696	△ 4,495	201	—
売上高 Net sales	77,782	81,510	3,728	4.8%
売上原価 Cost of sales	50,294	53,471	3,177	6.3%
売上総利益 Gross profit	27,488	28,039	551	2.0%
運送費、保管料 Transportation and storage	3,121	3,244	122	3.9%
広告宣伝費 Advertising	629	567	△ 62	△9.9%
販売促進費 Sales promotion	869	898	28	3.3%
研究開発費 Research and development	1,952	2,335	382	19.6%
管理費、その他 Other, net	12,020	13,891	1,871	15.6%
販売費及び一般管理費 SG&A expenses	18,593	20,937	2,343	12.6%
宝酒造 Takara Shuzo	1,108	2,595	1,487	134.2%
宝酒造インターナショナルグループ Takara Shuzo International Group	2,573	3,587	1,013	39.4%
タカラバイオ グループ Takara Bio Group	4,537	423	△ 4,114	△90.7%
その他 Other	732	686	△ 45	△6.2%
調整額 Adjustment	△ 57	△ 191	△ 133	—
営業利益(△:損失) Operating income(△:loss)	8,894	7,101	△ 1,792	△20.2%
受取利息・配当金 Interest and Dividends income	464	535	71	15.4%
その他営業外収益 Other, net	219	211	△ 8	△3.9%
営業外収益 Non-operating income	683	746	62	9.2%
支払利息 Interest and discounts expenses	75	91	16	22.0%
その他営業外費用 Other, net	249	56	△ 193	△77.5%
営業外費用 Non-operating expenses	324	148	△ 176	△54.4%
経常利益(△:損失) Ordinary income(△:loss)	9,253	7,700	△ 1,553	△16.8%
特別利益 Extraordinary income	903	19	△ 884	△97.8%
特別損失 Extraordinary loss	22	27	5	22.6%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	10,134	7,692	△ 2,442	△24.1%
法人税、住民税及び事業税 Current income taxes	2,499	2,754	255	10.2%
法人税等調整額 Deferred income taxes	551	△ 514	△ 1,065	—
四半期純利益(△:損失) Net income(△:loss)	7,083	5,451	△ 1,632	△23.0%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	1,841	486	△ 1,355	△73.6%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	5,241	4,965	△ 276	△5.3%
設備投資額(有形・無形) Capital expenditures	1,050	2,004	953	90.8%
減価償却費(有形・無形) Depreciation and Amortization	2,143	2,337	193	9.0%
のれん償却額 Amortization of goodwill	226	280	54	24.0%

営業外収益 Non-operating income	受取利息 64、受取配当金 471 など Interest income 64, Dividends income 471, etc.
営業外費用 Non-operating expenses	支払利息 91 (支払利息 80、社債利息 11) など (前期:為替差損 145 など) Interest expense 91 (Interest expense 80, Interest on bonds 11), etc. (FY2023:Foreign exchange losses 145, etc.)
特別利益 Extraordinary income	固定資産売却益 11 など (前期:受取保険金 652 など) Gain on sales of noncurrent assets 11, etc. (FY2023:Insurance income 652, etc.)
特別損失 Extraordinary loss	固定資産除売却損 27 Loss on sales and retirement of non-current assets 27

## 2. 宝酒造 :Takara Shuzo

### 要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第1四半期	2024年3月期 第1四半期 Apr. 1, 2023 - Jun. 30, 2023		
	実績 FY2023(1stQ) Actual(a)	実績 FY2024(1stQ) Actual(b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)
焼酎 Shochu	10,821	9,612	△ 1,209	△ 11.2%
清酒 Sake	2,395	2,292	△ 102	△ 4.3%
ソフトアルコール飲料 Light-alcohol refreshers	9,707	10,684	977	10.1%
その他酒類 Other liquors	1,399	1,486	87	6.3%
本みりん Hon Mirin	2,251	2,328	76	3.4%
その他調味料 Other seasonings	2,127	2,215	88	4.2%
原料用アルコール等 Raw alcohol	2,239	3,153	913	40.8%
売上高 Net sales	30,941	31,773	831	2.7%
売上原価 Cost of sales	23,767	23,389	△ 377	△ 1.6%
売上総利益 Gross profit	7,174	8,383	1,209	16.9%
運送費、保管料 Transportation and storage	2,026	1,926	△ 99	△ 4.9%
広告宣伝費 Advertising	586	451	△ 134	△ 23.0%
販売促進費 Sales promotion	540	510	△ 30	△ 5.6%
研究開発費 Research and development	91	92	1	1.3%
管理費、その他 Other, net	2,821	2,807	△ 14	△ 0.5%
販売費及び一般管理費 SG&A expenses	6,065	5,788	△ 277	△ 4.6%
営業利益(△:損失) Operating income(△:loss)	1,108	2,595	1,487	134.2%
営業外収益 Non-operating income	166	254	88	53.4%
営業外費用 Non-operating expenses	203	61	△ 141	△ 69.8%
経常利益(△:損失) Ordinary income(△:loss)	1,071	2,789	1,718	160.4%
特別利益 Extraordinary gain	—	3	3	—
特別損失 Extraordinary loss	3	17	13	330.6%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	1,067	2,776	1,708	160.1%
法人税、住民税及び事業税 Current income taxes	568	1,083	515	90.6%
法人税等調整額 Deferred income taxes	△ 227	△ 251	△ 24	—
四半期純利益(△:損失) Net income(△:loss)	725	1,943	1,217	167.8%
設備投資額(有形・無形) Capital expenditures	233	166	△ 66	△ 28.7%
減価償却費(有形・無形) Depreciation and Amortization	587	600	13	2.3%



### 3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

#### 要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第1四半期	2024年3月期 第1四半期 Apr. 1, 2023 - Jun. 30, 2023		
	実績 FY2023(1stQ) Actual(a)	実績 FY2024(1stQ) Actual(b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)
海外酒類事業 Overseas Alcoholic beverages business	3,848	4,889	1,040	27.0%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	25,980	33,140	7,159	27.6%
その他 Other	2,797	198	△ 2,599	△ 92.9%
連結消去 Elimination	△ 3,256	△ 796	2,460	—
売上高 Net sales	29,371	37,432	8,061	27.4%
売上原価 Cost of sales	20,234	25,228	4,993	24.7%
売上総利益 Gross profit	9,136	12,203	3,067	33.6%
運送費、保管料 Transportation and storage	1,015	1,239	223	22.0%
広告宣伝費 Advertising	30	32	1	5.7%
販売促進費 Sales promotion	205	236	30	14.9%
管理費、その他 Other, net	5,311	7,108	1,797	33.8%
販売費及び一般管理費 SG&A expenses	6,562	8,616	2,053	31.3%
海外酒類事業 Overseas Alcoholic beverages business	967	1,585	618	63.9%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	1,980	2,478	498	25.2%
その他 Other	2,518	△ 125	△ 2,644	—
連結消去 Elimination	△ 2,892	△ 351	2,540	—
営業利益(△:損失) Operating income(△:loss)	2,573	3,587	1,013	39.4%
営業外収益 Non-operating income	36	84	48	132.9%
営業外費用 Non-operating expenses	47	74	26	56.9%
経常利益(△:損失) Ordinary income(△:loss)	2,562	3,597	1,035	40.4%
特別利益 Extraordinary gain	0	7	7	—
特別損失 Extraordinary loss	0	5	4	—
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	2,563	3,600	1,037	40.5%
法人税、住民税及び事業税 Current income taxes	743	969	225	30.4%
法人税等調整額 Deferred income taxes	86	45	△ 40	△ 47.1%
四半期純利益(△:損失) Net income(△:loss)	1,732	2,585	852	49.2%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	285	348	63	22.3%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	1,447	2,236	789	54.5%
設備投資額(有形・無形) Capital expenditures	342	791	448	130.7%
減価償却費(有形・無形) Depreciation and Amortization	435	560	125	28.9%
のれん償却額 Amortization of goodwill	93	129	36	38.4%

#### 4. タカラバイオグループ :Takara Bio Group

##### 要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第1四半期	2024年3月期 第1四半期 Apr. 1, 2023 - Jun. 30, 2023		
	実績 FY2023(1stQ) Actual(a)	実績 FY2024(1stQ) Actual(b)	増減 Change (b-a)	率(b/a-1) YOY% (b/a-1)
試薬 Reagents	12,043	6,909	△ 5,133	△ 42.6%
機器 Instruments	267	220	△ 46	△ 17.5%
受託 CDMO	1,291	1,366	75	5.8%
遺伝子医療 Gene Therapy	499	679	180	36.1%
売上高 Net sales	14,102	9,176	△ 4,925	△ 34.9%
売上原価 Cost of sales	3,977	2,683	△ 1,294	△ 32.5%
売上総利益 Gross profit	10,124	6,493	△ 3,631	△ 35.9%
運送費、保管料 Transportation and storage	150	134	△ 16	△ 10.8%
広告宣伝費 Advertising	10	11	0	5.9%
販売促進費 Sales promotion	131	166	34	26.3%
研究開発費 Research and development	1,859	2,240	381	20.5%
管理費、その他 Other, net	3,434	3,517	82	2.4%
販売費及び一般管理費 SG&A expenses	5,586	6,069	483	8.6%
営業利益(△:損失) Operating income(Δ:loss)	4,537	423	△ 4,114	△ 90.7%
営業外収益 Non-operating income	78	119	40	51.9%
営業外費用 Non-operating expenses	23	33	10	43.8%
経常利益(△:損失) Ordinary income(Δ:loss)	4,593	509	△ 4,083	△ 88.9%
特別利益 Extraordinary income	902	1	△ 900	△ 99.8%
特別損失 Extraordinary loss	16	5	△ 11	△ 67.4%
税金等調整前四半期純利益(△:損失) Income before income taxes(Δ:loss)	5,479	505	△ 4,973	△ 90.8%
法人税、住民税及び事業税 Current income taxes	875	377	△ 497	△ 56.9%
法人税等調整額 Deferred income taxes	667	△ 204	△ 871	—
四半期純利益(△:損失) Net income(Δ:loss)	3,936	333	△ 3,603	△ 91.5%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	28	13	△ 15	△ 53.3%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	3,907	319	△ 3,588	△ 91.8%
設備投資額(有形・無形) Capital expenditures	451	998	546	120.9%
減価償却費(有形・無形) Depreciation and Amortization	979	1,047	67	6.9%
のれん償却額 Amortization of goodwill	132	150	18	13.8%

## 5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

### 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	2022年3月期 第1四半期 FY2022 (1stQ)	2023年3月期 第1四半期 FY2023 (1stQ)	2024年3月期 第1四半期 FY2024 (1stQ)	前対比 Change from FY2023(1stQ)	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	66,969	67,317	65,378	68,806	77,782	81,510	3,728	4.8%
売上原価 <i>Cost of sales</i>	40,387	40,844	40,020	40,470	50,294	53,471	3,177	6.3%
(売上高原価率) <i>(Ratio to Net sales)</i>	60.3%	60.7%	61.2%	58.8%	64.7%	65.6%	+0.9pt	1.5%
売上総利益 <i>Gross profit</i>	26,582	26,473	25,358	28,335	27,488	28,039	551	2.0%
販売費及び一般管理費 <i>SG&amp;A expenses</i>	22,582	22,924	23,426	15,995	18,593	20,937	2,343	12.6%
(売上高販管費率) <i>(Ratio to Net sales)</i>	33.7%	34.1%	35.8%	23.2%	23.9%	25.7%	+1.8pt	7.5%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	4,000	3,548	1,932	12,339	8,894	7,101	Δ 1,792	Δ 20.2%
(売上高営業利益率) <i>(Ratio to Net Sales)</i>	6.0%	5.3%	3.0%	17.9%	11.4%	8.7%	-2.7pt	Δ 23.8%
販売促進費、販売促進引当金繰入 <i>Sales promotion and allowance for s.p.</i>	8,426	8,676	8,718	816	869	898	28	3.3%
(売上高販促費率) <i>(Ratio to Net sales)</i>	12.6%	12.9%	13.3%	1.2%	1.1%	1.1%	-0.0pt	Δ 1.4%
研究開発費 <i>R&amp;D expenses</i>	1,111	1,037	1,262	1,384	1,952	2,335	382	19.6%
(売上高研究開発費率) <i>(Ratio to Net sales)</i>	1.7%	1.5%	1.9%	2.0%	2.5%	2.9%	+0.4pt	14.1%
設備投資額(有形・無形) <i>Capital expenditures</i>	1,085	1,613	1,550	3,775	1,050	2,004	953	90.8%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	1,578	1,637	1,995	1,985	2,143	2,337	193	9.0%
のれん償却額 <i>Amortization of goodwill</i>	215	213	217	212	226	280	54	24.0%

### 宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	2022年3月期 第1四半期 FY2022 (1stQ)	2023年3月期 第1四半期 FY2023 (1stQ)	2024年3月期 第1四半期 FY2024 (1stQ)	前対比 Change from FY2023(1stQ)	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	36,772	36,009	37,601	29,794	30,941	31,773	831	2.7%
売上原価 <i>Cost of sales</i>	22,161	21,868	23,015	22,203	23,767	23,389	Δ 377	Δ 1.6%
(売上高原価率) <i>(Ratio to Net sales)</i>	60.3%	60.7%	61.2%	74.5%	76.8%	73.6%	-3.2pt	Δ 4.2%
売上総利益 <i>Gross profit</i>	14,610	14,140	14,586	7,590	7,174	8,383	1,209	16.9%
販売費及び一般管理費 <i>SG&amp;A expenses</i>	13,759	13,967	13,854	6,112	6,065	5,788	Δ 277	Δ 4.6%
(売上高販管費率) <i>(Ratio to Net sales)</i>	37.4%	38.8%	36.8%	20.5%	19.6%	18.2%	-1.4pt	Δ 7.1%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	851	172	731	1,478	1,108	2,595	1,487	134.2%
(売上高営業利益率) <i>(Ratio to Net sales)</i>	2.3%	0.5%	1.9%	5.0%	3.6%	8.2%	+4.6pt	128.1%
販売促進費、販売促進引当金繰入 <i>Sales promotion and allowance for s.p.</i>	8,152	8,418	8,535	489	540	510	Δ 30	Δ 5.6%
(売上高販促費率) <i>(Ratio to Net sales)</i>	22.2%	23.4%	22.7%	1.6%	1.7%	1.6%	-0.1pt	Δ 8.0%
設備投資額(有形・無形) <i>Capital expenditures</i>	79	642	188	154	233	166	Δ 66	Δ 28.7%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	527	540	693	623	587	600	13	2.3%

### 宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	2022年3月期 第1四半期 FY2022 (1stQ)	2023年3月期 第1四半期 FY2023 (1stQ)	2024年3月期 第1四半期 FY2024 (1stQ)	前対比 Change from FY2023(1stQ)	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	18,270	19,819	18,616	21,068	29,371	37,432	8,061	27.4%
売上原価 <i>Cost of sales</i>	12,721	14,259	13,237	14,333	20,234	25,228	4,993	24.7%
(売上高原価率) <i>(Ratio to Net sales)</i>	69.6%	71.9%	71.1%	68.0%	68.9%	67.4%	-1.5pt	Δ 2.2%
売上総利益 <i>Gross profit</i>	5,549	5,559	5,379	6,735	9,136	12,203	3,067	33.6%
販売費及び一般管理費 <i>SG&amp;A expenses</i>	4,399	4,881	5,245	4,995	6,562	8,616	2,053	31.3%
(売上高販管費率) <i>(Ratio to Net sales)</i>	24.1%	24.6%	28.2%	23.7%	22.3%	23.0%	+0.7pt	3.0%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	1,150	678	133	1,740	2,573	3,587	1,013	39.4%
(売上高営業利益率) <i>(Ratio to Net sales)</i>	6.3%	3.4%	0.7%	8.3%	8.8%	9.6%	+0.8pt	9.4%
設備投資額(有形・無形) <i>Capital expenditures</i>	261	607	934	199	342	791	448	130.7%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	247	292	352	406	435	560	125	28.9%
のれん償却額 <i>Amortization of goodwill</i>	92	87	93	92	93	129	36	38.4%

### タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2019年3月期 第1四半期 FY2019 (1stQ)	2020年3月期 第1四半期 FY2020 (1stQ)	2021年3月期 第1四半期 FY2021 (1stQ)	2022年3月期 第1四半期 FY2022 (1stQ)	2023年3月期 第1四半期 FY2023 (1stQ)	2024年3月期 第1四半期 FY2024 (1stQ)	前対比 Change from FY2023(1stQ)	
							増減 Change	率 YOY%
売上高 <i>Net sales</i>	8,847	8,650	6,938	15,272	14,102	9,176	Δ 4,925	Δ 34.9%
売上原価 <i>Cost of sales</i>	3,491	2,734	2,234	2,133	3,977	2,683	Δ 1,294	Δ 32.5%
(売上高原価率) <i>(Ratio to Net sales)</i>	39.5%	31.6%	32.2%	14.0%	28.2%	29.2%	+1.0pt	3.7%
売上総利益 <i>Gross profit</i>	5,355	5,916	4,703	13,138	10,124	6,493	Δ 3,631	Δ 35.9%
販売費及び一般管理費 <i>SG&amp;A expenses</i>	3,811	3,664	4,009	4,633	5,586	6,069	483	8.6%
(売上高販管費率) <i>(Ratio to Net sales)</i>	43.1%	42.4%	57.8%	30.3%	39.6%	66.1%	+26.5pt	67.0%
営業利益(△:損失) <i>Operating income(Δ:loss)</i>	1,544	2,251	693	8,504	4,537	423	Δ 4,114	Δ 90.7%
(売上高営業利益率) <i>(Ratio to Net sales)</i>	17.5%	26.0%	10.0%	55.7%	32.2%	4.6%	-27.6pt	Δ 85.7%
研究開発費 <i>R&amp;D expenses</i>	1,014	939	1,172	1,294	1,859	2,240	381	20.5%
(売上高研究開発費率) <i>(Ratio to Net sales)</i>	11.5%	10.9%	16.9%	8.5%	13.2%	24.4%	+11.2pt	85.2%
設備投資額(有形・無形) <i>Capital expenditures</i>	678	361	281	3,313	451	998	546	120.9%
減価償却費(有形・無形) <i>Depreciation and Amortization</i>	669	677	815	808	979	1,047	67	6.9%
のれん償却額 <i>Amortization of goodwill</i>	123	125	123	120	132	150	18	13.8%

6. 2024年3月期 第1四半期 参考資料 :Reference Data for the First Quarter Ended June 30, 2023

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆ 為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries  
(円 : Yen)

	2023年3月期 第1四半期	2024年3月期 第1四半期 Apr. 1, 2023 - Jun. 30, 2023	
	実績 FY2023(1stQ) Actual(a)	実績 FY2024(1stQ) Actual(b)	前期差 Change(b-a)
米ドル : US dollar	116.34	132.40	16.06
ポンド : Pound	155.96	160.93	4.97
ユーロ : Euro	130.40	142.13	11.73
人民元 : Yuan	18.31	19.34	1.03
100ウォン : 100 Won	9.64	10.39	0.75
インドルピー : Rupee	1.55	1.61	0.06
オーストラリアドル : Australian dollar	84.23	90.56	6.33

◆ 売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2023(1stQ)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	4,168
宝酒造インターナショナルグループ 計 Net sales of Takara Shuzo International Group	3,593
海外酒類事業 Overseas Alcoholic beverages business	440
海外日本食材卸事業 Japanese food wholesale business in overseas markets	3,231
その他および調整額 Other / Adjustment	△ 78
タカラバイオグループ 計 Net sales of Takara Bio Group	574
試薬 Reagents	485
機器 Instruments	10
受託 CDMO	7
遺伝子医療 Gene Therapy	70

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2023年3月期第1四半期 実績 FY2023(1stQ) Actual			2024年3月期第1四半期 実績 FY2024(1stQ) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	30,941	—	—	31,773	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	29,371	29,335	99.9%	37,432	37,231	99.5%
タカラバイオグループ Takara Bio Group	14,102	8,736	62.0%	9,176	5,949	64.8%
その他および調整額 Other / Adjustment	3,367	—	—	3,128	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	77,782	38,072	48.9%	81,510	43,181	53.0%
※ タカラバイオグループ除く Takara Group except for Takara Bio Group	63,680	29,335	46.1%	72,334	37,231	51.5%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2023年3月期第1四半期 実績 FY2023(1stQ) Actual		2024年3月期第1四半期 実績 FY2024(1stQ) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造 Takara Sake USA Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	11,485 1,336	1,479 172	11,792 1,561	956 126
宝酒造食品 (中国) Takara Shuzo Foods Co.,Ltd. (China)	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	9,657 176	Δ 144 Δ 2	12,629 244	Δ 577 Δ 11
トマーチン (英国) The Tomatin Distillery Co.,Ltd (U.K.)	千 ポ ン ド :Thousands of Pound 百 万 円 :Millions of Yen	7,402 1,154	2,417 377	7,968 1,282	2,723 438
エイジ・インターナショナル (米国) AGE INTERNATIONAL,INC. (U.S.)	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	8,803 1,024	4,119 479	12,299 1,628	5,428 718
フーデックスグループ (欧州) FOODEX Group (Europe)	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	61,461 8,014	6,426 838	66,876 9,505	5,074 721
タザキフーズ (英国) TAZAKI FOODS LTD. (U.K.)	千 ポ ン ド :Thousands of Pound 百 万 円 :Millions of Yen	16,517 2,576	630 98	19,043 3,064	1,103 177
ミューチャルトレーディング (米国) Mutual Trading Co., Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	116,175 13,515	6,531 759	140,371 18,585	9,880 1,308
ニッポンフード (豪州) Nippon Food Supplies Company Pty Ltd (Austraria)	千 AUS ドル :Thousands of Australian dollar 百 万 円 :Millions of Yen	14,313 1,205	1,124 94	15,835 1,434	1,048 94
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	4,346	246	3,310	169
タカラバイオヨーロッパS.A.S. (連結) Takara Bio Europe S.A.S. Consolidated	千 ユ ー ロ :Thousands of Euro 百 万 円 :Millions of Yen	10,554 1,376	2,165 282	7,273 1,033	Δ 861 Δ 122
宝生物工程(大連) Takara Biotechnology (Dalian) Co.,Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	86,668 1,586	30,499 558	43,216 835	5,876 113
宝日医生物技術(北京) Takara Biomedical Technology(Beijing) Co., Ltd.	千 元 :Thousands of Yuan 百 万 円 :Millions of Yen	154,335 2,825	25,553 467	57,307 1,108	3,005 58
タカラリアバイオメディカル Takara Korea Biomedical Inc.	百 万 ウ ォ ン :Millions of Won 百 万 円 :Millions of Yen	3,598 346	419 40	3,297 342	445 46
タカラバイオDSSインド DSS Takara Bio India Private Limited	千 イ ン ド ル ヒ ー :Thousands of Rupee 百 万 円 :Millions of Yen	370,550 574	47,251 73	117,968 189	20,579 33
タカラバイオUSA Takara Bio USA, Inc.	千 US ドル :Thousands of US dollar 百 万 円 :Millions of Yen	38,106 4,433	9,023 1,049	29,135 3,857	1,676 221

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo  
(百万円 :Millions of Yen)

	対前期増減 Change from FY2023(1stQ)		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+1,209	+192	+1,017
(参考) 原価コストダウン Reference :Cost reduction	Δ 1,419 ※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「Δ」で表示  
\*An increasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結) 要約損益計算書(p.1)における「その他」の内訳  
Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

		2023年3月期第1四半期 実績 FY2023(1stQ) Actual		2024年3月期第1四半期 実績 FY2024(1stQ) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
ワイン輸入販売事業 Import and sale of wine		1,631	396	1,536	411
物流事業 Transportation		3,449	145	3,315	108
不動産事業(宝ホールディングス) Real estate business(Takara Holdings)		124	102	125	104
その他 Other		2,858	87	2,645	62
「その他」計 Total "Other"		8,064	732	7,623	686